📇 Rhumatologue · FORT DE FRANCE · (972) · Libéral

MME CLAIRE CHARLES-EDOUARD-GUITTON

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
106.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 FORT DE FRANCE (972)LibéralRPPS 10001669901

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

CABINET DU DR CLAIRE CHARLES-EDOUARD-GUITTON
DE BRIAND 106 BOULEVARD HUYGUES DESPOINTES, 97234 FORT DE FRANCE
☎ 0596641664Activité de soin et de pharmacie
C.P.M.I. DE LA RUCHE
7 RTE DE LA FOLIE, 97200 FORT DE FRANCE
☎ 0596552598Activité de soin et de pharmacie

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Advancing the use of real world evidence in health technology assessment: insights from a multi-stakeholder workshop

Frontiers in pharmacology · 2023

📚 16 citations🎯 RCR 5.17Top 7% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Introduction: Real-world evidence (RWE) in health technology assessment (HTA) holds significant potential for informing healthcare decision-making. A multistakeholder workshop was organised by the European Health Data and Evidence Network (EHDEN) and the GetReal Institute to explore the status, challenges, and opportunities in incorporating RWE into HTA, with a focus on learning from regulatory initiatives such as the European Medicines Agency (EMA) Data Analysis and Real World Interrogation Network (DARWIN EU®).Methods: The workshop gathered key stakeholders from regulatory agencies, HTA organizations, academia, and industry for three panel discussions on RWE and HTA integration. Insights and recommendations were collected through panel discussions and audience polls. The workshop outcomes were reviewed by authors to identify key themes, challenges, and recommendations.Results: The workshop discussions revealed several important findings relating to the use of RWE in HTA. Compared with regulatory processes, its adoption in HTA to date has been slow. Barriers include limited trust in RWE, data quality concerns, and uncertainty about best practices. Facilitators include multidisciplinary training, educational initiatives, and stakeholder collaboration, which could be facilitated by initiatives like EHDEN and the GetReal Institute. Demonstrating the impact of “driver projects” could promote RWE adoption in HTA.Conclusion: To enhance the integration of RWE in HTA, it is crucial to address known barriers through comprehensive training, stakeholder collaboration, and impactful exemplar research projects. By upskilling users and beneficiaries of RWE and those that generate it, promoting collaboration, and conducting “driver projects,” can strengthen the HTA evidence base for more informed healthcare decisions.

Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda

Pediatric blood & cancer · 2024

📚 8 citations🎯 RCR 2.05🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background The lack of accurate population‐based information on childhood cancer stage and survival in low‐income countries is a barrier to improving childhood cancer outcomes. Methods In this study, data from the Rwanda National Cancer Registry (RNCR) were examined for children aged 0–14 diagnosed in 2013–2017 for the eight most commonly occurring childhood cancers: acute lymphoblastic leukaemia, Hodgkin lymphoma (HL), Burkitt lymphoma (BL), non‐Hodgkin lymphoma excluding BL, retinoblastoma, Wilms tumour, osteosarcoma and rhabdomyosarcoma. Utilising the Toronto Childhood Cancer Stage Guidelines Tier 1, the study assigned stage at diagnosis to all, except HL, and conducted active follow‐ups to calculate 1‐, 3‐ and 5‐year observed and relative survival by cancer type and stage at diagnosis. Results The cohort comprised 412 children, of whom 49% ( n = 202) died within 5 years of diagnosis. Five‐year survival ranged from 28% (95% confidence interval [CI]: 12.5%–45.6%) for BL to 68% (CI: 55%–78%) for retinoblastoma. For the cancers for which staging was carried out, it was assigned for 83% patients ( n = 301 of 362), with over half (58%) having limited or localised stage at diagnosis. Stage was a strong predictor of survival; for example, 3‐year survival was 70% (95% CI: 45.1%–85.3%) and 11.8% (2.0%–31.2%) for limited and advanced non‐HL, respectively ( p < .001). Conclusion This study is only the second to report on stage distribution and stage‐specific survival for childhood cancers in sub‐Saharan Africa. It demonstrates the feasibility of the Toronto Stage Guidelines in a low‐resource setting, and highlights the value of population‐based cancer registries in aiding our understanding of the poor outcomes experienced by this population.

Ebola Virus Disease Features Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in the Rhesus Macaque Model

The Journal of infectious diseases · 2023

📚 7 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Ebola virus (EBOV) disease (EVD) is one of the most severe and fatal viral hemorrhagic fevers and appears to mimic many clinical and laboratory manifestations of hemophagocytic lymphohistiocytosis syndrome (HLS), also known as macrophage activation syndrome. However, a clear association is yet to be firmly established for effective host-targeted, immunomodulatory therapeutic approaches to improve outcomes in patients with severe EVD. Methods Twenty-four rhesus monkeys were exposed intramuscularly to the EBOV Kikwit isolate and euthanized at prescheduled time points or when they reached the end-stage disease criteria. Three additional monkeys were mock-exposed and used as uninfected controls. Results EBOV-exposed monkeys presented with clinicopathologic features of HLS, including fever, multiple organomegaly, pancytopenia, hemophagocytosis, hyperfibrinogenemia with disseminated intravascular coagulation, hypertriglyceridemia, hypercytokinemia, increased concentrations of soluble CD163 and CD25 in serum, and the loss of activated natural killer cells. Conclusions Our data suggest that EVD in the rhesus macaque model mimics pathophysiologic features of HLS/macrophage activation syndrome. Hence, regulating inflammation and immune function might provide an effective treatment for controlling the pathogenesis of acute EVD.

Cookies & analyse de trafic

MME CLAIRE CHARLES-EDOUARD-GUITTON

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (27) — classées par pathologie

Transversal8

Épidémiologie & registres4

Case report / série3

Pédiatrie3

Revue générale3

Vraie vie / RWE2

Corticothérapie1

Essai clinique1

Goutte1

Lupus1

Qualité de vie / PROMs1

SAPL1

Vascularites des gros vaisseaux1

Partager cette fiche